Acute Myeloid Leukemia, Adult Clinical Trials

26 clinical trials for Acute Myeloid Leukemia, Adult across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML — RECRUITING · PHASE3
• Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) — RECRUITING · PHASE3
• CLAG-GO for Patients With Persistent, Relapsed or Refractory AML — RECRUITING · PHASE2
• A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML — RECRUITING · PHASE1
• Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia — RECRUITING · PHASE2
• Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) — RECRUITING
• A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients — RECRUITING · PHASE1
• Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome — RECRUITING · PHASE3
• First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients — RECRUITING · PHASE1
• Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML — RECRUITING · NA
• Lentivirally Redirected CD123 Autologous T Cells in AML — TERMINATED · PHASE1
• Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia — COMPLETED · PHASE2
• Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy — TERMINATED · PHASE1
• Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease — WITHDRAWN
• Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 — COMPLETED · PHASE2
• Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia — COMPLETED
• Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult — OTHER · PHASE2
• Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients — NOT_YET_RECRUITING · PHASE1
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. — TERMINATED · PHASE2
• Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation — TERMINATED · PHASE2
• RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. — OTHER
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features — OTHER · PHASE2
• Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy — OTHER
• Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay — OTHER · NA
• Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia — OTHER · PHASE3

Refine this search